This episode, titled Optimizing Subcutaneous Therapies in NSCLC: Practical Integration, Patient Selection, and Workflow ...
Vietnam Investment Review on MSN
Celltrion launches AVTOZMA subcutaneous formulation in US
INCHEON, South Korea, March 16, 2026 /PRNewswire/ -- Celltrion, Inc. today announced that AVTOZMA® (tocilizumab-anoh) ...
Avtozma is among the first wave of tocilizumab biosimilars with both intravenous and subcutaneous formulations approved and commercially available in the United States.
Detailed price information for Rani Therapeutics Holdings Inc Cl A (RANI-Q) from The Globe and Mail including charting and trades.
ADBRY ® (tralokinumab) 12‑month real‑world data from the TRACE study evaluating the safety and effectiveness of AD ...
According to Maximize Market Research, the Global Heparin Market is projected to reach USD 8.7 billion in 2025 and is ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, “Eisai”) and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts, CEO: Christopher A. Viehbacher, “Biogen”) announced ...
Tenax Therapeutics is a "Sell" given its negative risk/reward skew even under bullish scenarios. Here's what investors need ...
The global nasal drug delivery technology market is projected to grow at a CAGR of approximately 7% over the next five years. This growth is driven by the increasing demand for non-invasive and ...
Recommendation is based on peer-reviewed clinical data supporting long-term effectiveness and safety durability in patients with papillary-only disease treated with ANKTIVA plus BCG1.CULVER CITY, ...
Eisai Co., Ltd. (Headquarters: Tokyo, CEO: Haruo Naito, "Eisai") and Biogen Inc. (Nasdaq: BIIB, Corporate headquarters: Cambridge, Massachusetts ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results